![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
1 Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee
2 Division of Clinical Pharmacology, Departments of Medicine and Pharmacologly, Vanderbilt University, Nashville, Tennessee
The binding of propranolol to plasma has been determined at therapeutic concentrations by equilibrium dialysis in man (93.2%), monkey (99.2%), dog (96.6%) and rat (92.2%) and correlated with its kinetics of disposition after intravenous administration. In nine human subjects the clearance of propranolol from the blood was high and relatively constant at 1.05 liters/min. The apparent volume of distribution (V d
) which varied 2-fold was proportional to the disposition rate constant, . In all the species examined Vd increased as free drug concentration increased in the order monkey:dog:man:rat, such that the volume of distribution of free drug was constant. This occurred despite large variations in drug clearance among the species (14-92 ml/kg/min), which resulted from differences in hepatic extraction ratio, relative magnitude of liver blood flow and extrahepatic metabolism. When the influence of a variable drug clearance was taken into account, increased drug binding was associated with a decrease in drug half-life. Such differences in binding account in part for species differences in half-life and are entirely responsible for interindividual variation in half-life in man after intravenous administration. These data are consistent with the hypothesis that plasma binding decreases the half-life of propranolol by increasing the rate of drug delivery to its site of elimination. This results because only volume of distribution is dependent on the free drug in the circulation, whereas more than the free fraction of the drug in the circulation is available for clearance by the organs of elimination.
This article has been cited by other articles:
|
|
 |
|
  H. Wong, S. J. Grossman, S. A. Bai, S. Diamond, M. R. Wright, J. E. Grace Jr., M. Qian, K. He, K. Yeleswaram, and D. D. Christ THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION Drug Metab. Dispos., December 1, 2004; 32(12): 1359 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Feng, J. Loo, and J. Wright Disposition of the Antipsychotic Agent CI-1007 in Rats, Monkeys, Dogs, and Human Cytochrome P450 2D6 Extensive Metabolizers. Species Comparison and Allometric Scaling Drug Metab. Dispos., October 1, 1998; 26(10): 982 - 988. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Brynne, M. O. Karlsson, and L. K. Paalzow Concentration-Effect Relationship of l-Propranolol and Metoprolol in Spontaneous Hypertensive Rats after Exercise-Induced Tachycardia J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1152 - 1158. [Abstract] [Full Text]
|
|
|
|
|
|
H. Matsushima, H. Kamimura, Y. Soeishi, T. Watanabe, S. Higuchi, and M. Tsunoo PHARMACOKINETICS AND PLASMA PROTEIN BINDING OF TAMSULOSIN HYDROCHLORIDE IN RATS, DOGS, AND HUMANS Drug Metab. Dispos., March 1, 1998; 26(3): 240 - 245. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Panagia, Y. Taira, G. L. Bryson, P. S. Tappia, and N. S. Dhalla Effect of {beta}-Adrenoceptor Antagonists on Phospholipid N-Methylation Activities of Cardiac Sarcolemma Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(3): 239 - 245. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Q. Kong Jr, J. J. Goldberger, M. Parker, T. Wang, and A. H. Kadish Circadian Variation in Human Ventricular Refractoriness Circulation, September 15, 1995; 92(6): 1507 - 1516. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
